- Home
- » Tags
- » Pracinostat
Top View
- HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin As A
- New and Emerging HDAC Inhibitors for Cancer Treatment
- Core Submission Dossier
- Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models
- Melatonin in the Context of Circadian Oscillator Genes and Signaling
- Histone Deacetylases
- Epigenetic Modulators As Therapeutic Targets in Prostate Cancer Inês Graça1,2, Eva Pereira-Silva1, Rui Henrique1,3,4, Graham Packham5, Simon J
- Pracinostat Plus Azacitidine in Older Patients With
- MIR-18A and RUNX1T1 by TIAN HE Subm
- Discovery of Novel Potential Selective HDAC8 Inhibitors by Combine
- (Mesenchymal) Stem Cells
- Erasers of Histone Acetylation: the Histone Deacetylase Enzymes
- Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-Hdacis) in the Treatment of Solid Malignancies
- Identification and Characterization of AES-135, a Hydroxamic Acid-Based
- Histone Deacetylase Inhibitors for Cancer Therapy: an Evolutionarily Ancient Resistance Response May Explain Their Limited Success
- Advances in Epigenetic Cancer Therapeutics
- AR Annexes 2017 Collated
- ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types Anderly C
- 51) International Patent Classification: (84) Designated States (Unless Otherwise Indicated, for Every C12N 15/10 (2006.01) Kind of Regional Protection Available
- Histone Deacetylase Inhibitors As Potential COVID-19 Virus RNA-Dependent RNA Polymerase Inhibitors: a Molecular Docking and Dynamics Study
- Age-Dependent Fecundity of Podisus Nigrispinus
- Recent Developments in Epigenetic Cancer Therapeutics: Clinical Advancement and Emerging Trends Kunal Nepali1 and Jing‑Ping Liou1,2*
- Biomedicines
- Non-Coding DNA in IBD: from Sequence Variation in Gut: First Published As 10.1136/Gutjnl-2018-317516 on 28 January 2019
- Comparative Study Between Valproic Acid Combined with Conventional
- To Treat Breast Cancer Brain Metastasis
- Emerging Role of Histone Deacetylase Inhibitors As Anti-Breast-Cancer
- Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016